Curium Pharma Data Breach — Class Action Review

Curium Pharma is a specialized radiopharmaceutical manufacturing and nuclear medicine company that develops, produces, and distributes life-saving diagnostic and therapeutic imaging products globally. Because of its specialized position at the intersection of advanced life sciences and healthcare delivery, the organization maintains vast repositories of highly sensitive data. This includes comprehensive patient and clinical trial participant records, detailed physician ordering histories, diagnostic imaging data, and intricate supply chain logs tied to medical institutions and hospitals across the country. The sheer volume of protected health information and proprietary medical data managed by Curium makes it an extensive repository of personally identifiable information.

In 2025, Curium Pharma reported a significant data security incident to the New Hampshire Attorney General's Office, prompting urgent legal scrutiny and notification mandates. While the precise mechanics of the breach are still under active investigation, security events impacting specialized pharmaceutical and medical manufacturing firms typically involve sophisticated cyberattacks, such as ransomware deployments, unauthorized intrusion into enterprise resource planning networks, or compromises of third-party vendors and supply chain logistics partners. In the context of pharmaceutical operations, threat actors frequently target interconnected digital environments that bridge administrative systems, clinical data management platforms, and operational networks.

The exposure resulting from the Curium Pharma breach encompasses categories of information that carry severe and long-lasting risks for affected individuals. Compromised data sets frequently include full legal names, dates of birth, Social Security numbers, medical record numbers, health insurance policy details, and specific diagnostic or treatment information. When exposed, this combination of medical and financial data creates profound vulnerabilities. Unlike transient credit card fraud, compromised health information and Social Security numbers cannot be easily reset or replaced. This exposes victims to sustained threats of medical identity theft, fraudulent insurance claims, unauthorized prescription routing, and targeted financial fraud that can persist for years.

As an entity handling sensitive medical and personal records, Curium Pharma was bound by stringent legal obligations to safeguard this information. Under the Health Insurance Portability and Accountability Act (HIPAA), as well as state-level data protection frameworks and consumer protection statutes, the company had a clear duty to implement robust administrative, physical, and technical safeguards. These regulations require continuous network monitoring, rigorous encryption standards, vendor risk management, and prompt vulnerability patching. The occurrence of a data breach of this scale strongly indicates potential failures in these foundational security duties, suggesting that existing safeguards were inadequate to prevent unauthorized access.

For individuals who have received a formal data breach notification letter from Curium Pharma, this document serves as a legal acknowledgement that their sensitive information was compromised due to corporate security failures. Legally, receiving this notice establishes the standing necessary to participate in class action litigation aimed at holding the company accountable. Affected individuals do not need to demonstrate actual financial loss or identity theft to seek legal redress; the increased risk of future harm and the invasion of privacy are sufficient grounds. Our firm is actively investigating potential class action claims on a contingency fee basis, meaning affected individuals pay nothing out of pocket and our firm only collects a fee if a successful recovery is secured.